Any current/future new fundraising through debt or equity?

The transcript does not specifically mention any current or planned fundraising through debt or equity. The company has significant ongoing and planned capital expenditure: approximately INR 2,500 crore planned for FY27 and a major INR 10,000 crore investment plan at the Odisha site over 4-5 years. There is no explicit discussion of raising funds via debt or equity to finance these investments. Management focuses on internal funding and operational efficiencies to support growth. No direct references are made to equity issuance or debt raising during the Q4 & FY26 earnings call.

Any current/future capex/capital investment/strategic investment?

INR2,300 crore investment at new Odisha site over next 2 years for fourth-generation refrigerant gases (20,000 MT pa capacity), including backward integration into hydrofluoric acid (30,000 MT) and electronic grade HF. Capex of ~INR2,500 crore planned for FY27 aligned with long-term growth priorities. Recent trial runs of KAPLAR plant for capacitor-grade BOPP films to be capitalized shortly. BOPP-BOPE line expected to commence production in July. INR180 crore investment in a state-of-the-art BOPA (polyamide) line, operational by September 2027, India's first of its kind. Commissionin

Future growth expectations in sales/revenue/volumes?

Chemicals business expected to grow 15-20% in FY27 despite pricing pressures and volatility. Strong product pipeline across specialty chemicals from intermediates through to AI critical for growth. Fluoropolymer segment ramp-up anticipated in the latter part of FY27 with high-margin contracts (e.g., Chemours arrangement) starting Q4. Refrigerant gases (HFOs) capacity expansion underway, targeting commissioning by Feb 2028, with early customer interest and sales ramp-up expected. Newer chemical products, including pharma and agro intermediates, progressing with expected commercialization and re

Future growth expectations in earnings/operating earnings/profits/EPS?

SRF Limited expects Chemicals business growth of 15% to 20% in FY27, driven by capacity expansions and product pipeline. Incremental capacity enhancements in refrigerant gases, including next-generation HFOs (HFO-1234yf, HFO-1234ze, HFO-1233zd), will contribute significantly. Ramp-up of fluoropolymer specialty grades and fluoropolymer capacity expected in the second half of FY27. Strong progress on aluminum foil exports and specialty product approvals to drive revenue growth through 2027. Investments of around INR2,500 crore planned in FY27, going towards BOPP, BOPA lines, specialty chemicals,

Current/ Expected Orderbook/ Pending Orders?

The current order book and pending orders were not explicitly quantified in the transcript. Demand remains strong across key segments, and the company is working to fulfill all existing orders. There is significant customer interest, especially in fluoropolymers and specialty chemicals. Capacity expansions and debottlenecking exercises are underway to meet growing orders and expected demand. Export shipments have started in aluminum, supporting ramp-up in outcomes. The Chemours arrangement for fluoropolymers is on track with revenue ramp-up expected in Q4 FY26 and accelerating in FY27. The com

IN US

Sale is live|00:00:00left today

SRF LtdQ1 FY26Chemicals & Petrochemicals

SRF Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,762P/E: 41.9Market Cap: ₹79.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Chemicals business expected to grow 15-20% in FY27 despite pricing pressures and volatility.
→Strong product pipeline across specialty chemicals from intermediates through to AI critical for growth.
→Fluoropolymer segment ramp-up anticipated in the latter part of FY27 with high-margin contracts (e.g., Chemours arrangement) starting Q4.
→Refrigerant gases (HFOs) capacity expansion underway, targeting commissioning by Feb 2028, with early customer interest and sales ramp-up expected.
→Newer chemical products, including pharma and agro intermediates, progressing with expected commercialization and revenue contribution over next 2-3 years.
→Exports of aluminum foil specialty grades have begun and are set to improve in 2027.
→Continued focus on operational efficiencies and technological interventions to sustain margins and volumes amid pricing normalization.

Margin guidance

Category 3

→SRF Limited expects Chemicals business growth of 15% to 20% in FY27, driven by capacity expansions and product pipeline.
→Incremental capacity enhancements in refrigerant gases, including next-generation HFOs (HFO-1234yf, HFO-1234ze, HFO-1233zd), will contribute significantly.
→Ramp-up of fluoropolymer specialty grades and fluoropolymer capacity expected in the second half of FY27.
→Strong progress on aluminum foil exports and specialty product approvals to drive revenue growth through 2027.
→Investments of around INR2,500 crore planned in FY27, going towards BOPP, BOPA lines, specialty chemicals, and more.
→Operational efficiencies and technological interventions are expected to sustain competitive margins despite pricing pressures.
→Ongoing approvals and commercialization timelines indicate revenue ramp-ups mostly in the second half of FY27 and beyond.
→Overall, the company aims to sustain volume growth and margin improvements despite a volatile macro environment.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not specifically mention any current or planned fundraising through debt or equity.
→The company has significant ongoing and planned capital expenditure: approximately INR 2,500 crore planned for FY27 and a major INR 10,000 crore investment plan at the Odisha site over 4-5 years.
→There is no explicit discussion of raising funds via debt or equity to finance these investments.
→Management focuses on internal funding and operational efficiencies to support growth.
→No direct references are made to equity issuance or debt raising during the Q4 & FY26 earnings call.

Order book

→The current order book and pending orders were not explicitly quantified in the transcript.
→Demand remains strong across key segments, and the company is working to fulfill all existing orders.
→There is significant customer interest, especially in fluoropolymers and specialty chemicals.
→Capacity expansions and debottlenecking exercises are underway to meet growing orders and expected demand.
→Export shipments have started in aluminum, supporting ramp-up in outcomes.
→The Chemours arrangement for fluoropolymers is on track with revenue ramp-up expected in Q4 FY26 and accelerating in FY27.
→The company is focused on reducing product approval timelines to capitalize on incoming orders rapidly.
→While not quantified, order momentum indicates robust near-term and medium-term demand visibility.

Capex plans

Yes

→INR2,300 crore investment at new Odisha site over next 2 years for fourth-generation refrigerant gases (20,000 MT pa capacity), including backward integration into hydrofluoric acid (30,000 MT) and electronic grade HF.
→Capex of ~INR2,500 crore planned for FY27 aligned with long-term growth priorities.
→Recent trial runs of KAPLAR plant for capacitor-grade BOPP films to be capitalized shortly.
→BOPP-BOPE line expected to commence production in July.
→INR180 crore investment in a state-of-the-art BOPA (polyamide) line, operational by September 2027, India's first of its kind.
→Commissioning of new dipping line at Manali in Technical Textiles shortly.
→Pharma intermediates plant 2 coming up; pipeline of molecules expanding with focus on regulatory starting materials.
→Debottlenecking exercise expanding HFC capacity beyond 65,000 MT.
→Strategic fluoropolymer investments progressing; Chemours arrangement on track for Q4 revenue ramp-up.

How does SRF Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1SRF Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like SRF Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio